TRACON Pharmaceutical (TCON) Tops Q3 EPS by 40c

TRACON Pharmaceutical (NASDAQ: TCON) reported Q3 EPS of $0.33, $0.40 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $493.26 million versus the consensus estimate of $3.55 million.

For earnings history and earnings-related data on TRACON Pharmaceutical (TCON) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• ClearSign Technologies (CLIR) Tops Q2 EPS by 8c
• Coty (COTY) Misses Q4 EPS by 1c, offers outlook